MEI Pharma (MEI Pharma) Operating Income : $15.88 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Operating Income?

MEI Pharma's Operating Income for the three months ended in Dec. 2023 was $-11.93 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $15.88 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. MEI Pharma's Operating Income for the three months ended in Dec. 2023 was $-11.93 Mil. MEI Pharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, MEI Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was %.

Good Sign:

MEI Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.

MEI Pharma's 5-Year average Growth Rate for Operating Margin % was 43.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MEI Pharma's annualized ROC % for the quarter that ended in Dec. 2023 was -307.71%. MEI Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -378.81%.

MEI Pharma Operating Income Historical Data

The historical data trend for MEI Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Operating Income Chart

MEI Pharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Operating Income

Get a 7-Day Free Trial

-46.25

-25.70

-60.42

-75.48

-36.76

MEI Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															8.93	-16.39	-11.08	55.28	-11.93

MEI Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.88 Mil.

MEI Pharma (NAS:MEIP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MEI Pharma's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-47.72 * ( 1 - 0% )	/	( (15.399	+	15.617)	/ 2 )
=	-47.72	/	15.508
=	-307.71 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	101.251	-	5.994	-	( 82.202	-	max(0, 8.564	-	88.422	+	82.202	))
=	15.399

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	78.538	-	4.787	-	( 59.48	-	max(0, 8.038	-	66.172	+	59.48	))
=	15.617

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

MEI Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-47.72	/	( ( (12.829 + max(-1.289, 0))	+	(12.366 + max(-0.331, 0)) )	/	2 )
=	-47.72	/	( ( 12.829	+	12.366 )	/	2 )
=	-47.72	/	12.5975
=	-378.81 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.22)	-	(5.994	+	0	+	1.515)
=	-1.289

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.692)	-	(4.787	+	0	+	2.236)
=	-0.331

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

MEI Pharma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-11.93	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

MEI Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (MEI Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

0JW9:UK

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Executives

Taheer Datoo	director	181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Sujay Kango	director	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie	officer: Chief Medical Officer	C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson	10 percent owner	5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc.	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam	10 percent owner	111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File	officer: CFO and Corporate Secretary	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc	10 percent owner	2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii	director	C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130